Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.
Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J, Reiter RE. Weiner AB, et al. Among authors: czernin j. Eur Urol Open Sci. 2024 Oct 15;70:36-42. doi: 10.1016/j.euros.2024.09.004. eCollection 2024 Dec. Eur Urol Open Sci. 2024. PMID: 39483519 Free PMC article.
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Nikitas J, et al. Among authors: czernin j. Eur Urol. 2024 Jun;85(6):517-520. doi: 10.1016/j.eururo.2024.01.021. Epub 2024 Mar 16. Eur Urol. 2024. PMID: 38494380 Free PMC article. Clinical Trial.
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Weber M, et al. Among authors: czernin j. Eur Urol. 2024 Jun;85(6):511-516. doi: 10.1016/j.eururo.2024.01.019. Epub 2024 Mar 15. Eur Urol. 2024. PMID: 38490855 Free article.
Fibroblast Activation Protein Expression in Sarcomas.
Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Crane JN, et al. Among authors: czernin j. Sarcoma. 2023 Jun 9;2023:2480493. doi: 10.1155/2023/2480493. eCollection 2023. Sarcoma. 2023. PMID: 37333052 Free PMC article.
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.
Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, Rahbar K, Tagawa ST, Czernin J, El-Haddad G, Wong CC, Zhang Z, Wilke C, Mirante O, Morris MJ, Fizazi K. Herrmann K, et al. Among authors: czernin j. EClinicalMedicine. 2024 Oct 4;77:102862. doi: 10.1016/j.eclinm.2024.102862. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39430616 Free PMC article.
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. Imani F, et al. J Nucl Med. 2009 Apr;50(4):513-9. doi: 10.2967/jnumed.108.058396. Epub 2009 Mar 16. J Nucl Med. 2009. PMID: 19289420 Free article.
416 results